Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Immunosuppressants Stories

2013-12-24 08:23:55

HORSHOLM, Denmark, Dec. 24, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus(® )was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. Envarsus(®) is Veloxis' once-daily formulation of tacrolimus...

2013-12-17 12:24:39

BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, will soon publish a comprehensive market analysis and a forecast though 2022 for the Crohn's disease drug market. Other upcoming reports covering immune and inflammatory diseases will examine the uptake and impact of new products that treat rheumatoid arthritis and psoriatic arthritis. (Logo:...

2013-12-16 08:27:16

Oral 5-Aminosalicylates Will Remain the Preferred Treatment Regimen for Early Lines of Therapy, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through an examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has experienced steady growth among recently treated Crohn's disease (CD)...

2013-12-16 08:26:04

However, Novel Agents Will Face Reimbursement and Uptake Challenges if Robust Superiority over Anti-TNFs is Lacking, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when considering the most important attributes for prescribing emerging therapies for Crohn's disease (CD) and ulcerative colitis (UC),...

2013-12-12 12:26:15

Recent Changes Include Earlier and More-Aggressive Treatment, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 12, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that physician-reported patient shares for Novartis's Gilenya and Biogen Idec's Tysabri are 8 percent and 10 percent among relapsing-remitting multiple sclerosis (RR-MS) patients treated with a...

2013-12-11 08:30:33

HORSHOLM, Denmark, Dec. 11, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced dosing of the first patient in ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of ENVARSUS® (formerly LCP Tacro(TM)) in kidney transplant recipients. The ASERTAA study is designed to compare the pharmacokinetics (PK) of ENVARSUS®, a once-daily tacrolimus tablet, to generic twice daily tacrolimus capsules in stable African-American renal...

2013-12-10 23:20:12

Reportbuyer.com just published a new market research report: Biosimilar Opportunities in an Evolving Market. London (PRWEB) December 10, 2013 Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two...

2013-12-10 12:26:23

While Improved Efficacy Will Determine Uptake, Cost-Related Issues Will Drive Favorable Formulary Inclusion of Emerging Agents, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that lack of initial response or waning efficacy over time are the main reasons that patients discontinue treatment with leading...

2013-12-09 08:29:18

Filanesib demonstrated clinical activity as a single agent and in combination with proteasome inhibitors BOULDER, Colo., Dec. 9, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) announced positive data for newly named filanesib (ARRY-520) as a single agent and in combination with proteasome inhibitors (PI) in patients with multiple myeloma (MM) at the 2013 Annual Meeting of the American Society of Hematology. (Logo:...

2013-12-07 23:02:25

MarketReportsOnline.com offers “Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)” in its store. Key drug manufacturers of the global rheumatoid arthritis market like Abbvie Inc. (Humira), Amgen Inc. (Enbrel), Johnson & Johnson (Remicade), Roche Holdings AG (Actemra) are profiled in the report. Dallas, TX (PRWEB) December 07, 2013 The report titled "Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)" provides an in-depth...